(Bloomberg) -- Moderna Inc. executives won’t attend a planned White House summit on Covid-19 vaccines on Tuesday, according to a person familiar with the matter.

The drugmaker and rival Pfizer Inc. are both seeking emergency-use authorizations for their experimental vaccines. A group of outside advisers to the U.S. Food and Drug Administration is scheduled to consider the case for clearing Pfizer’s shot Thursday, and an advisory panel will scrutinize Moderna’s shot at a meeting on Dec. 17.

The White House summit is intended to boost public confidence in the vaccines. FDA officials are expected to appear at the meeting, and it would be inappropriate for the drugmaker to attend while its application for authorization is pending with the agency, the person said.

©2020 Bloomberg L.P.